Insider Selling: FibroGen, Inc (FGEN) CEO Sells 18,900 Shares of Stock

FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,900 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $46.60, for a total transaction of $880,740.00. Following the transaction, the chief executive officer now owns 3,109,555 shares in the company, valued at approximately $144,905,263. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

FibroGen, Inc (NASDAQ FGEN) traded down $2.65 during trading hours on Monday, reaching $44.50. 451,259 shares of the company were exchanged, compared to its average volume of 618,471. FibroGen, Inc has a 1-year low of $19.25 and a 1-year high of $60.15. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16.

A number of large investors have recently bought and sold shares of the stock. SG Americas Securities LLC grew its stake in FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its stake in FibroGen by 1.7% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock valued at $939,000 after buying an additional 474 shares during the last quarter. Principal Financial Group Inc. grew its stake in FibroGen by 0.4% in the 1st quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock valued at $3,354,000 after buying an additional 504 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in FibroGen by 15.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 696 shares during the last quarter. Finally, Tudor Investment Corp ET AL grew its stake in FibroGen by 7.1% in the 2nd quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock valued at $391,000 after buying an additional 799 shares during the last quarter. Institutional investors and hedge funds own 57.42% of the company’s stock.

Several brokerages have recently commented on FGEN. Mizuho restated a “hold” rating and set a $61.00 price target on shares of FibroGen in a research note on Thursday, November 9th. Citigroup increased their price target on shares of FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday, August 8th. ValuEngine lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Friday. Stifel Nicolaus restated a “buy” rating and set a $80.00 price target on shares of FibroGen in a research note on Thursday, September 14th. Finally, William Blair restated an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. FibroGen has a consensus rating of “Buy” and a consensus target price of $65.67.

TRADEMARK VIOLATION WARNING: “Insider Selling: FibroGen, Inc (FGEN) CEO Sells 18,900 Shares of Stock” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/04/thomas-b-neff-sells-18900-shares-of-fibrogen-inc-fgen-stock-2.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply